Once-weekly alendronate: Two year subgroup efficacy analyses in postmenopausal women with osteoporosis.

被引：0
|
作者：
Bone, H
Felsenberg, D
Greenwald, M
Schnitzer, T
Kaur, A
Cudny, M
Peverly, C
Orloff, J
Santora, A
机构：
[1] Michigan Bone & Mineral Clin PC, Detroit, MI USA
[2] Free Univ Berlin Klinikum, Berlin, Germany
[3] Desert Med Advances, Palm Desert, CA USA
[4] Northwestern Univ, Chicago, IL 60611 USA
[5] Merck Res Labs, Rahway, NJ USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2001年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S526 / S526
页数：1
相关论文
共 50 条
  • [31] Age-related efficacy of alendronate, risedronate, and etidronate in postmenopausal women with osteoporosis.
    Ishida, Y.
    Taguchi, T.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S15 - S15
  • [32] Effect of once weekly risedronate on bone density in postmenopausal osteoporosis.
    Delaney, MF
    Shaw, J
    Hurwitz, S
    LeBoff, MS
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S286 - S286
  • [33] Reversal of HIV-1-associated osteoporosis with once-weekly alendronate
    Negredo, E
    Martínez-López, E
    Paredes, R
    Rosales, J
    Pérez-Alvarez, N
    Holgado, S
    Gel, S
    del Rio, L
    Tena, X
    Rey-Joly, C
    Clotet, B
    AIDS, 2005, 19 (03) : 343 - 345
  • [34] The effects of once-weekly alendronate 70 mg on bone metabolism of postmenopausal women in Korea.
    Kim, H
    Shon, H
    Choi, J
    Lee, H
    Kim, E
    Park, I
    Park, I
    Kim, B
    Lee, I
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S394 - S394
  • [35] Once-weekly alendronate has superior antiresorptive efficacy and comparable upper gastrointestinal tolerability to once-weekly risedronate
    Hochberg, M
    Rosen, C
    Bonnick, S
    Saag, K
    Broy, S
    McClung, GI
    Chen, E
    Petruschke, RA
    de Papy, AE
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S292 - S293
  • [36] Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis (vol 20, pg 2031, 2004)
    Sebba, AI
    Bonnick, SL
    Kagan, R
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (02) : 325 - 325
  • [37] TREATMENT WITH ONCE-WEEKLY ALENDRONATE 70 MG COMPARED TO ONCE-WEEKLY RISEDRONATE 35 MG IN WOMEN WITH POSTMENOPAUSALE OSTEOPOROSIS: A RANDOMIZED DOUBLE-BLIND STUDY
    Pietschmann, Peter
    JOURNAL FUR MINERALSTOFFWECHSEL, 2005, 12 (01): : 36 - 38
  • [38] Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis
    Schnitzer, T
    Bone, HG
    Crepaldi, G
    Adami, S
    McClung, M
    Kiel, D
    Felsenberg, D
    Recker, RR
    Tonino, RP
    Roux, C
    Pinchera, A
    Foldes, AJ
    Greenspan, SL
    Levine, MA
    Emkey, R
    Santora, AC
    Kaur, A
    Thompson, DE
    Yates, J
    Orloff, JJ
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2000, 12 (01) : 1 - 12
  • [39] Efficacy, safety and tolerability of once weekly (80mg vs 160mg) oral alendronate over 2 years in postmenopausal osteoporosis.
    Brown, JP
    Banville, C
    Jean, S
    Drake, WL
    Kendler, DL
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S375 - S375
  • [40] The change of bone markers after once-weekly low dose alendronate in postmenopausal women with moderate bone loss
    Choi, H.
    Kim, S.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S326 - S326
12345